Contact
Prosensa
Innovative RNA-based therapeutics acting at the cause of the disease
Introduced at a biopartnering meeting, the ceedd was fascinated by Prosensa's science focusing on RNA-modulating therapeutics. Prosensa's approach was strongly aligned with the ceedd strategy – utilizing the leading edge of technology to discover treatments to devastating diseases with significant unmet medical needs. Its RNA-based therapeutic research promises many opportunities for novel commercially attractive treatments for Duchenne Muscular Dystrophy (DMD), and its relationship with the ceedd will provide access to GSK's diverse drug development capabilities.
Prosensa is a biotech company dedicated to the commercialization of products for the healthcare market based on RNA-modulating therapeutics. During the development of this technology, it became clear that many opportunities exist for the development of these products into novel commercially attractive products. Prosensa's technology platform can be applied to a wide array of therapeutic fields such as genetic disorders, infectious diseases and cancer. The company's primary focus today is to develop life-changing therapeutics for genetic neuromuscular and neurodegenerative disorders such as DMD, Myotonic Dystrophy and Huntington's Disease.
The GSK-Prosensa alliance fits the ceedd strategy to actively seek to collaborate with world-class biotech companies that are performing highly innovative, original and transformative science.
View Company Website ›› | Latest Alliance News ›› | ceedd of Innovation Story ››
